Chen Tso-Hsiao, Kao Yuan-Chung, Chen Bing-Chang, Chen Cheng-Hsien, Chan Paul, Lee Horng-Mo
Department of Internal Medicine, Taipei Medical University, Wan-Fang Hospital, Taiwan.
Eur J Pharmacol. 2006 Jul 17;541(3):138-46. doi: 10.1016/j.ejphar.2006.05.002.
Dipyridamole is a nucleoside transport inhibitor and a non-selective phosphodiesterase inhibitor. However, the mechanisms by which dipyridamole exerts its anti-inflammatory effects are not completely understood. In the present study, we investigated the role of mitogen-activated kinase phosphatase-1 (MKP-1) in dipyridamole's anti-inflammatory effects. We show that dipyridamole inhibited interleukin-6 and monocyte chemoattractant protein-1 secretion, inducible nitric oxide synthase protein expression, nitrite accumulation, and cyclooxygenase-2 (COX-2) induction in lipopolysaccharide (LPS)-activated RAW 264.7 macrophages. Dipyridamole inhibited the nuclear factor kappa B (NF-kappaB) signaling pathway as demonstrated by inhibition of the inhibitor of NF-kappaB (IkappaB) phosphorylation, IkappaB degradation, p65 translocation from the cytosol to the nucleus, and transcription of the reporter gene. Dipyridamole also inhibited LPS-stimulated p38 mitogen-activated protein kinase (p38 MAPK) and IkappaB kinase-beta (IKK-beta) activities in RAW 264.7 cells. A p38 MAPK inhibitor, SB 203580, inhibited LPS-stimulated COX-2 expression and IKK-beta activation suggesting that LPS may activate the NF-kappaB signaling pathway via upstream p38 MAPK activation. Furthermore, dipyridamole stimulated transient activation of MKP-1, a potent inhibitor of p38 MAPK function. Knockdown of MKP-1 by transfecting MKP-1 siRNA or inhibition of MKP-1 by the specific inhibitor, triptolide, significantly reduced the inhibitory effects of dipyridamole on COX-2 expression induced by LPS. Taken together, these data suggest that dipyridamole exerts its anti-inflammatory effect via activation of MKP-1, which dephosphorylates and inactivates p38 MAPK. Inactivation of p38 MAPK in turn inhibits IKK-beta activation and subsequently the NF-kappaB signaling pathway that mediates LPS-induced cyclooxygenase-2 expression in RAW 264.7 cells.
双嘧达莫是一种核苷转运抑制剂和非选择性磷酸二酯酶抑制剂。然而,双嘧达莫发挥其抗炎作用的机制尚未完全明确。在本研究中,我们调查了丝裂原活化蛋白激酶磷酸酶-1(MKP-1)在双嘧达莫抗炎作用中的作用。我们发现双嘧达莫可抑制脂多糖(LPS)激活的RAW 264.7巨噬细胞中白细胞介素-6和单核细胞趋化蛋白-1的分泌、诱导型一氧化氮合酶蛋白表达、亚硝酸盐积累以及环氧合酶-2(COX-2)的诱导。双嘧达莫抑制核因子κB(NF-κB)信号通路,表现为抑制NF-κB抑制剂(IkappaB)的磷酸化、IkappaB降解、p65从胞质溶胶转位至细胞核以及报告基因的转录。双嘧达莫还抑制RAW 264.7细胞中LPS刺激的p38丝裂原活化蛋白激酶(p38 MAPK)和IkappaB激酶-β(IKK-β)活性。一种p38 MAPK抑制剂SB 203580可抑制LPS刺激的COX-2表达和IKK-β激活,这表明LPS可能通过上游p38 MAPK激活来激活NF-κB信号通路。此外,双嘧达莫可刺激MKP-1的瞬时激活,MKP-1是p38 MAPK功能的有效抑制剂。通过转染MKP-1 siRNA敲低MKP-1或用特异性抑制剂雷公藤内酯醇抑制MKP-1,可显著降低双嘧达莫对LPS诱导的COX-2表达的抑制作用。综上所述,这些数据表明双嘧达莫通过激活MKP-1发挥其抗炎作用,MKP-1使p38 MAPK去磷酸化并使其失活。p38 MAPK失活进而抑制IKK-β激活,随后抑制介导RAW 264.7细胞中LPS诱导的环氧合酶-2表达的NF-κB信号通路。